AbbVie’s PARP inhibitor fails in PhIII trials
AbbVie’s experimental PARP inhibitor veliparib has failed to meet key targets in two late-stage studies testing its potential in lung and breast cancer.
Read More
Tag: Veliparib
Orphan status for AbbVie’s PARP inhibitor
AbbVie’s experimental lung cancer drug veliparib has picked up Orphan Drug status in the US, opening the door to potential tax credits, waived fees, protocol assistance and exclusivity benefits.
Read More
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
